SG177225A1 - Cancer-related protein kinases - Google Patents

Cancer-related protein kinases Download PDF

Info

Publication number
SG177225A1
SG177225A1 SG2011095569A SG2011095569A SG177225A1 SG 177225 A1 SG177225 A1 SG 177225A1 SG 2011095569 A SG2011095569 A SG 2011095569A SG 2011095569 A SG2011095569 A SG 2011095569A SG 177225 A1 SG177225 A1 SG 177225A1
Authority
SG
Singapore
Prior art keywords
epha2
lmtk2
arg
tyk2
ack1
Prior art date
Application number
SG2011095569A
Other languages
English (en)
Inventor
Axel Ullrich
Jens Ruhe
Stefan Hart
Sylvia Streit
Chee Hong Wong
Boon Tin Chua
Han Kiat Ho
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG177225A1 publication Critical patent/SG177225A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG2011095569A 2006-12-01 2007-12-03 Cancer-related protein kinases SG177225A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86817306P 2006-12-01 2006-12-01

Publications (1)

Publication Number Publication Date
SG177225A1 true SG177225A1 (en) 2012-01-30

Family

ID=39468190

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2011095569A SG177225A1 (en) 2006-12-01 2007-12-03 Cancer-related protein kinases

Country Status (5)

Country Link
US (1) US20110008347A1 (enExample)
EP (1) EP2094850B1 (enExample)
JP (1) JP2010511382A (enExample)
SG (1) SG177225A1 (enExample)
WO (1) WO2008066498A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
JP2010515921A (ja) * 2007-01-11 2010-05-13 ジェネンテック， インコーポレイテッド 腫瘍と関連している遺伝的変異
WO2009028639A1 (ja) 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited 抗ｅｐｈａ２抗体
JP2011509079A (ja) 2007-12-24 2011-03-24 オックスフォード ビオトヘラペウトイクス エルティーディー． エフリンａ型受容体１０タンパク質
CN101978060A (zh) * 2008-02-05 2011-02-16 乌菲尔有限公司 新fer样蛋白、包含其的药物组合物及其使用方法
EA024751B8 (ru) 2008-06-04 2020-01-31 Амген Инк. Мутанты fgf21 и их применение
EP2165710A1 (en) 2008-09-19 2010-03-24 Institut Curie Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
EP2169071A1 (en) * 2008-09-29 2010-03-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Rodent cancer model for human FGFR4 Arg388 polymorphism
EP2358749B1 (en) 2008-10-10 2018-07-18 Amgen, Inc Fgf21 mutants and uses thereof
JP5439494B2 (ja) * 2008-10-21 2014-03-12 バイエル ヘルスケア エルエルシー 肝細胞癌と関連するシグネチャ遺伝子の同定
US8318484B2 (en) 2008-11-12 2012-11-27 Tengion, Inc. Isolated renal cells and uses thereof
DK2881402T3 (en) 2009-02-12 2017-08-28 Cell Signaling Technology Inc Mutant ROS expression in human liver cancer
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
SMT202400036T1 (it) 2009-05-05 2024-03-13 Amgen Inc Mutanti fgf21 e loro utilizzi
EP2336171A1 (en) * 2009-12-11 2011-06-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel targets for the treatment of proliferative diseases
US9517264B2 (en) 2010-04-15 2016-12-13 Amgen Inc. Human FGF receptor and β-Klotho binding proteins
EP2380909A1 (en) * 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PTK-7 protein involved in breast cancer
HUE058155T2 (hu) 2010-05-12 2022-07-28 Prokidney Bioaktív vesesejtek
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9587033B2 (en) 2010-11-15 2017-03-07 University Of Florida Research Foundation, Inc. Therapeutic and diagnostic applications targeting TNK-1
WO2012075158A1 (en) 2010-12-01 2012-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ror1 antibodies
RU2019103083A (ru) * 2011-11-30 2019-03-22 Дженентек, Инк. МУТАЦИИ ErbB3 ПРИ РАКЕ
EP3122375B1 (en) 2014-03-28 2021-03-03 University of Washington through its Center for Commercialization Breast and ovarian cancer vaccines
WO2016036172A1 (ko) 2014-09-03 2016-03-10 씨제이헬스케어 주식회사 단백질 키나제 억제제에 대한 감수성 예측용 바이오 마커 및 이의 용도
CN106795567B (zh) 2014-10-09 2021-07-30 豪夫迈·罗氏有限公司 在表皮生长因子受体激酶结构域中的突变
WO2016196141A1 (en) * 2015-05-29 2016-12-08 Ignyta, Inc. Compositions and methods for treating patients with rtk mutant cells
EP3365335B1 (en) 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
HK1254836A1 (zh) 2015-10-30 2019-07-26 Nbe-Therapeutics Ag 抗-ror1抗体
MX2018008926A (es) 2016-01-20 2019-01-10 Scripps Research Inst Composiciones de anticuerpo contra ror1 y métodos relacionados.
US11123372B2 (en) 2016-07-29 2021-09-21 Prokidney Bioactive renal cells for the treatment of chronic kidney disease
CN106480205A (zh) * 2016-11-11 2017-03-08 北京吉因加科技有限公司 用于同时检测多种突变类型的序列组合和探针
CN121401264A (zh) 2017-07-19 2026-01-27 伊尼塔公司 包括恩曲替尼的药物组合物
EP3665193A1 (en) 2017-08-07 2020-06-17 NBE Therapeutics AG Anthracycline-based antibody drug conjugates having high in vivo tolerability
WO2019077506A1 (en) 2017-10-17 2019-04-25 Ignyta, Inc. PHARMACEUTICAL COMPOSITIONS AND SOLID GALENIC FORMS
KR102078775B1 (ko) * 2017-11-29 2020-02-19 서울대학교산학협력단 항-ros1 항체 및 그의 용도
WO2019133752A1 (en) * 2017-12-28 2019-07-04 Development Center For Biotechnology A method for predicting drug efficacy
JP2022515198A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物
CN113474337A (zh) 2018-12-19 2021-10-01 奥瑞生物药品公司 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
CN113557301B (zh) * 2019-03-04 2025-03-07 公益财团法人东京都医学综合研究所 编码Trk片段的核酸构建体及其利用
CN110031626A (zh) * 2019-04-02 2019-07-19 浙江理工大学 一种用于胃肠道间质肿瘤迁移的标志物ack1及其应用
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
US20230115945A1 (en) 2019-12-30 2023-04-13 Tyra Biosciences, Inc. Aminopyrimidine compounds
MX2023007793A (es) 2020-12-30 2023-09-22 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas.
MX2023009954A (es) 2021-02-26 2023-11-09 Tyra Biosciences Inc Compuestos de aminopirimidina y métodos de uso de estos.
EP4547670A1 (en) 2022-06-29 2025-05-07 Tyra Biosciences, Inc. Polymorphic compounds and uses thereof
TW202416961A (zh) 2022-06-29 2024-05-01 美商泰拉生物科學公司 吲唑化合物
WO2024138112A1 (en) 2022-12-22 2024-06-27 Tyra Biosciences, Inc. Indazole compounds
WO2025129014A1 (en) 2023-12-15 2025-06-19 Tyra Biosciences, Inc. Indazole compounds for the treatment of cancer
WO2025222097A1 (en) 2024-04-19 2025-10-23 Tyra Biosciences, Inc. Indazole-based protac degraders and their anticancer activity
WO2025236094A1 (en) * 2024-05-14 2025-11-20 Narendran Arumugavadivel Identification, design and validation of public neoantigens for the treatment of down syndrome-associated leukemia
WO2026035809A1 (en) 2024-08-06 2026-02-12 Tyra Biosciences, Inc. Indazole compounds for the treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343940A (en) * 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
EP0031237B1 (en) * 1979-12-19 1984-10-17 National Research Development Corporation Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
DE3611194A1 (de) * 1986-04-04 1987-10-08 Bayer Ag Cancerostatisches mittel
US5217999A (en) * 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3920029C2 (de) * 1988-06-30 1999-05-20 Clariant Finance Bvi Ltd Farbstoffe zum Färben von Kunststoffen
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
SE517975C2 (sv) 2000-05-30 2002-08-13 Power Ab C Fackverkskonstruktion av balkar sammansatta till ett tredimensionellt ramverk samt användning av en sådan fackverkskonstruktion
JP2004533206A (ja) * 2000-10-11 2004-11-04 アバロン　ファーマシューティカルズ 化学療法のための標的としてのガン関連遺伝子
US20050191618A1 (en) 2001-05-18 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20060194265A1 (en) * 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
AU2003225535A1 (en) * 2002-01-31 2003-09-02 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer
JP2006174701A (ja) * 2003-02-24 2006-07-06 Research Association For Biotechnology 新規タンパク質およびそれをコードするｄｎａ
JP2005198640A (ja) * 2003-11-25 2005-07-28 Biomarker Science:Kk 遺伝子発現方法

Also Published As

Publication number Publication date
JP2010511382A (ja) 2010-04-15
WO2008066498A1 (en) 2008-06-05
EP2094850A4 (en) 2010-08-04
US20110008347A1 (en) 2011-01-13
EP2094850B1 (en) 2013-06-12
EP2094850A1 (en) 2009-09-02

Similar Documents

Publication Publication Date Title
US20110008347A1 (en) Cancer-related protein kinases
US9364477B2 (en) Mutant ROS expression in human cancer
US20100111944A1 (en) Method of diagnosing, classifying and treating endometrial cancer and precancer
US20100081153A1 (en) Cancer associated protein kinases and their uses
JP6387001B2 (ja) Ｃｄｋ阻害剤と関連するバイオマーカー
Goel et al. The unique N‐terminal region of SRMS regulates enzymatic activity and phosphorylation of its novel substrate docking protein 1
Andrés-Pons et al. In vivo functional analysis of the counterbalance of hyperactive phosphatidylinositol 3-kinase p110 catalytic oncoproteins by the tumor suppressor PTEN
CN100578227C (zh) 用于诊断和作为癌症治疗靶标的ttk
US9464313B2 (en) Biosensor for detecting RAF/KSR family kinase dimerization and uses thereof
US20190094229A1 (en) Methods of diagnosing, classifying and treating endometrial cancer and precancer
Hosoya et al. Identification of a SRC‐like tyrosine kinase gene, FRK, fused with ETV6 in a patient with acute myelogenous leukemia carrying at (6; 12)(q21; p13) translocation
WO2012075318A2 (en) Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer
Mayoral-Varo et al. Pharmacological Modulation of TRIB2 Stability in Melanoma Reveals CDK12/13 as Dominant Regulators and Potential Therapeutic Targets
Shillingford Insights into the Allosteric Regulation and Exploitation of the MAPK Phosphatases as Therapeutic Targets
Montecchini et al. A novel peptide biosensor for screening ABL1 activity in vitro: a challenge for precision therapy in BCR-ABL1 and BCR-ABL1 like leukemias.
CN117795340A (zh) 生物标志物及其用途
Mutic Effect of MAPK inhibition on cell cycle regulation of thymidine kinase 1 and [18F]-FLT PET
AU2007237228A1 (en) Cancer associated protein kinases and their uses
HK1210482B (en) Mutant ros expression in human liver cancer
JP2005245403A (ja) アポトーシス調節活性を測定する方法、及びアポトーシス調節活性を有する化合物のスクリーニング方法
HK1165007B (en) Mutant ros expression in human liver cancer